3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
40
Lymphoma, Non-Hodgkin
39
Lymphoma, Follicular
24
Lymphoma
22
Lymphoma, Large B-Cell, Diffuse
19
Lymphoma, Mantle-Cell
18
Lymphoma, B-Cell
10
Recurrence
9
Neoplasms
8
Lymphoma, B-Cell, Marginal Zone
8
Leukemia
6
Hodgkin Disease
6
Multiple Myeloma
4
Hematologic Diseases
4
Lymphoma, T-Cell, Peripheral
3
Advanced Solid Tumor
2
Waldenstrom Macroglobulinemia
1
Tumor Lysis Syndrome
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Interventions
ibrutinib
3
Rituximab
3
Cyclophosphamide
3
Bortezomib
3
tetulomab tetraxetan lu-177
2
ponatinib
2
fludarabine
2
cobomarsen
2
Vorinostat
2
Lutetium
2
enzalutamide
1
durvalumab
1
cirmtuzumab
1
acalabrutinib
1
Vincristine
1
Prednisone
1
Lutetium-177
1
Lenalidomide
1
KW-2478
1
Imatinib Mesylate
1
Ifosfamide
1
Hsp90 inhibitor KU757
1
Etoposide
1
Doxorubicin
1
Carboplatin
1
CA-4948
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Immune System Diseases
×
Bendamustine Hydrochloride
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts